The association between the 5-HTTLPR polymorphism of the serotonin transporter gene and the efficacy and tolerability of selective serotonin reuptake inhibitors

Ivanets N.N.

Sechenov First Moscow State Medical University (Sechenov University)

ORCID: 0000-0002-0013-5031

Kinkulkina M.A.

Sechenov First Moscow State Medical University (Sechenov University)

ORCID: 0000-0001-8386-758X

Tikhonova Yu.G.

Sechenov First Moscow State Medical University (Sechenov University)

ORCID: 0000-0001-6071-2796

Avdeeva T.I.

Sechenov First Moscow State Medical University (Sechenov University)

ORCID: 0000-0002-5109-1438

Ragimov A.A.

Center for Collective Use "Transfusion Medicine" of the I.M. Sechenov First Moscow State Medical University (Sechenov University)

Dashkova N.G.

Center for Collective Use "Transfusion Medicine" of the I.M. Sechenov First Moscow State Medical University (Sechenov University)

Kuznetsov O.E.

Center for Collective Use "Transfusion Medicine" of the I.M. Sechenov First Moscow State Medical University (Sechenov University)

Matveev A.V.

National Pharmacovigilance Research Center;
Medical Academy n. a. S.I. Georgievsky of Vernadskjy CFU, Simferopol

Izyumina T.A.

Sechenov First Moscow State Medical University (Sechenov University)

ORCID: 0000-0001-7432-863X

Orlov S.V.

Acad. I.P. Pavlov First Saint Petersburg State Medical University of the Ministry of Health of Russia

The association between the 5-HTTLPR polymorphism of the serotonin transporter gene and the efficacy and tolerability of selective serotonin reuptake inhibitors

Authors:

Ivanets N.N., Kinkulkina M.A., Tikhonova Yu.G., Avdeeva T.I., Ragimov A.A., Dashkova N.G., Kuznetsov O.E., Matveev A.V., Izyumina T.A., Orlov S.V.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2016;116(2): 46‑51

DOI: 10.17116/jnevro20161162146-51

Downloaded: 144

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Ivanets NN, Kinkulkina MA, Tikhonova YuG, et al. . The association between the 5-HTTLPR polymorphism of the serotonin transporter gene and the efficacy and tolerability of selective serotonin reuptake inhibitors. S.S. Korsakov Journal of Neurology and Psychiatry. 2016;116(2):46‑51. (In Russ.)
https://doi.org/10.17116/jnevro20161162146-51

Close metadata

OBJECTIVE

To search for the association between the 5-HTTLPR polymorphism of the serotonin transporter gene and the efficacy and tolerability of selective serotonin reuptake inhibitors (SSRIs).

MATERIAL AND METHODS

The complex clinical/psychopathological and genetic study of 38 patients with depression treated with SSRIs was carried out.

RESULTS AND CONCLUSION

The 5-HTTLPR polymorphism was associated with the rate of achievement of remission and tolerability of treatment: carriers of the SS genotype achieved remission less frequently and more frequently experienced side-effects.

Keywords:

pharmacogenetics

depression

antidepressants

5-HTTLPR

serotonin reuptake

Authors:

Ivanets N.N.

Sechenov First Moscow State Medical University (Sechenov University)

ORCID: 0000-0002-0013-5031

Kinkulkina M.A.

Sechenov First Moscow State Medical University (Sechenov University)

ORCID: 0000-0001-8386-758X

Tikhonova Yu.G.

Sechenov First Moscow State Medical University (Sechenov University)

ORCID: 0000-0001-6071-2796

Avdeeva T.I.

Sechenov First Moscow State Medical University (Sechenov University)

ORCID: 0000-0002-5109-1438

Ragimov A.A.

Center for Collective Use "Transfusion Medicine" of the I.M. Sechenov First Moscow State Medical University (Sechenov University)

Dashkova N.G.

Center for Collective Use "Transfusion Medicine" of the I.M. Sechenov First Moscow State Medical University (Sechenov University)

Kuznetsov O.E.

Center for Collective Use "Transfusion Medicine" of the I.M. Sechenov First Moscow State Medical University (Sechenov University)

Matveev A.V.

National Pharmacovigilance Research Center;
Medical Academy n. a. S.I. Georgievsky of Vernadskjy CFU, Simferopol

Izyumina T.A.

Sechenov First Moscow State Medical University (Sechenov University)

ORCID: 0000-0001-7432-863X

Orlov S.V.

Acad. I.P. Pavlov First Saint Petersburg State Medical University of the Ministry of Health of Russia

List of references:

Draft clinical guidelines: Recurrent Depressive Disorder. (In Russ.) https://psychiatr.ru/news/164
Kostyukova EG, Gorodnichev AV. Present-day therapy for recurrent depressive disorder: from research to clinical practice. From the book «Biological therapies of mental disorders (evidence-based medicine for clinical practice), ed. SN Mosolov, Moscow: Publisher «Social and Political Thought», 2012;251-272.
Brambilla P et al. Side-effect profile of fluoxetine in comparison with other SSRIs, tricyclic and newer antidepressants: a meta-analysis of clinical trial data. Pharmacopsychiatry. 2005;38:69-77. https://doi.org/10.1055/s-2005-837806
Sghendo L, Mifsud J. Understanding the molecular pharmacology of the serotonergic system: using fluoxetine as a model. Journal of Pharmacy and Pharmacology. 64:317-325. https://doi.org/10.1111/j.2042-7158.2011.01384.x
Tanti A, Belzung C. Open questions in current models of antidepressant action. British Journal of Pharmacology. 2010;159:1187-1200. https://doi.org/10.1111/j.1476-5381.2009.00585.x
Mosolov SN. Biological mechanisms of recurrent depression and antidepressants. From the book «Biological therapies of mental disorders (evidence-based medicine for clinical practice), ed. SN Mosolov, Moscow: Publisher «Social and Political Thought». 2012;273-305.
Hariri AR, Weinberger DR. Functional neuroimaging of genetic variation in serotonergic neurotransmission. Genes, Brain and Behavior. 2003;2:341-349. https://doi.org/10.1046/j.1601-1848.2003.00048.x
Kunugi H, Hattori M, Kato T, Tatsumi M, Sakai T, Sasaki T et al. Serotonin transporter gene polymorphisms: ethnic difference and possible association with bipolar affective disorder. Mol Psychiatry. 1997;2:457-462. https://doi.org/10.1038/sj.mp.4000334
Odgerel Z, Talati A, Hamilton SP, Levinson DF, Weissman MM. Genotyping serotonin transporter polymorphisms 5-HTTLPR and rs25531 in European- and African-American subjects from the National Institute of Mental Health’s Collaborative Center for Genomic Studies. Transl Psychiatry. 2013;3(9):307. https://doi.org/10.1038/tp.2013.80
Serretti A, Calati R, Mandelli L et al. Serotonin transporter gene variants and behavior: a comprehensive review. Curr Drug Targets. 2006;7:1659-1669. https://doi.org/10.2174/138945006779025419
Lesch KP, Bengel D, Heils A, Sabol SZ, Greenberg BD, Petri S, Benjamin J, Muller CR, Hamer DH, Murphy DL. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science. 1996;274:1527-1531. https://doi.org/10.1126/science.274.5292.1527
Little KY, McLaughlin DP, Zhang L, Livermore CS, Dalack GW, De McFinton PRI, Proposto ZS, Hill E, Cassin BJ, Watson SJ, Cook EH. Cocaine, ethanol, and genotype effects on human midbrain serotonin transporter binding sites and mRNA levels. Am J Psychiatry. 1998;155:207-213.
Heinz A, Jones DW, Mazzanti C, Goldman D, Ragan P, Hommer D, Linnoila M, Weinberger DR. A relationship between serotonin transporter genotype and in vivo protein expression and alcohol neurotoxicity. Biol Psychiatry. 2000;47:643-649. https://doi.org/10.1016/s0006-3223(99)00171-7
Naylor L, Dean B, Pereira A, Mackinnon A, Kouzmenko A, Copolov D. No association between the serotonin transporter-linked promoter region polymorphism and either schizophrenia or density of the serotonin transporter in human hippocampus. Mol Med. 1998;4:671-674.
Mann JJ, Huang Y-Y, Underwood M, Kassir SA, Oppenheim S, Kelly TM, Dwork AJ, Arango V. A serotonin transporter gene promoter polymorphism (5-HTTLPR) and prefrontalcortical binding in major depression and suicide. Arch Gen Psychiatry. 2000;57:729-738. https://doi.org/10.1001/archpsyc.57.8.729
Kaiser R, Muller-Oerlinghausen B, Filler D, Tremblay P-B, Berghofer A, Roots I, Brockmoller J. Correlation between serotonin uptake in human blood platelets with the 44-bp polymorphism and the 17-bp variable number of tandem repeat of the serotonin transporter. Am J Med Genet. 2002;114:323-328. https://doi.org/10.1002/ajmg.10119
Serretti A, Kato M, De Ronchi D et al. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Mol Psychiatry. 2007;12:247-257. https://doi.org/10.1038/sj.mp.4001926
Porcelli S, Fabbri C, Serretti A. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy. Eur Neuropsychopharmacol. 2012;22(4):239-258. https://doi.org/10.1016/j.euroneuro.2011.10.003
Smits K, Smits L, Peeters F, Schouten J, Janssen R, Smeets H, van Os J, Prins M. Serotonin transporter polymorphisms and the occurrence of adverse events during treatment with selective serotonin reuptake inhibitors. Int Clin Psychopharmacol. 2007;22(3):137-143. https://doi.org/10.1097/yic.0b013e328014822a
Perlis RH, Mischoulon D, Smoller JW, Wan YJ, Lamon-Fava S, Lin KM, Rosenbaum JF, Fava M. Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment. Biol Psychiatry. 2003;54(9):879-883. https://doi.org/10.1016/s0006-3223(03)00424-4
Ferreira Ade A, Neves FS, da Rocha FF et al. The role of 5-HTTLPR polymorphism in antidepressant-associated mania in bipolar disorder. J Affect Disord. 2009;112(1-3):267-272. https://doi.org/10.1016/j.jad.2008.04.012
Murphy GM Jr, Hollander SB, Rodrigues HE, Kremer C, Schatzberg AF. Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression. Arch Gen Psychiatry. 2004;61(11):1163-1169. https://doi.org/10.1001/archpsyc.61.11.1163
Popp J, Leucht S, Heres S, Steimer W. Serotonin transporter polymorphisms and side effects in antidepressant therapy — a pilot study. Pharmacogenomics. 7:2:159-166. https://doi.org/10.2217/14622416.7.2.159
Lanctôt KL, Rapoport MJ, Chan F et al. Genetic predictors of response to treatment with citalopram in depression secondary to traumatic brain injury. Brain Inj. 2010;24(7-8):959-969. https://doi.org/10.3109/02699051003789229
Hodgson K, Uher R, Crawford AA, Lewis G, O’Donovan MC, Keers R, Dernovsek MZ, Mors O, Hauser J, Souery D, Maier W, Henigsberg N, Rietschel M, Placentino A, Aitchison K, Farmer A, Davis O, McGuffin P. Genetic predictors of antidepressant side effects: a grouped candidate gene approach in the Genome-Based Therapeutic Drugs for Depression (GENDEP) Study. J Psychopharmacol. 2014;28(2):142-150. https://doi.org/10.1177/0269881113517957
Ng C, Sarris J, Singh A, Bousman C, Byron K, Peh LH, Smith DJ, Tan CH, Schweitzer I. Pharmacogenetic polymorphisms and response to escitalopram and venlafaxine over 8 weeks in major depression. Hum Psychopharmacol. 2013;28(5):516-522. https://doi.org/10.1002/hup.2340
Serretti A, Olgiati P, Bajo E, Bigelli M, De Ronchi D. A model to incorporate genetic testing (5-HTTLPR) in pharmacological treatment of major depressive disorders. World J Biol Psychiatry. 2011;12(7):501-515. https://doi.org//10.3109/15622975.2011.572998
Rebrova O. Statistical analysis of medical data. The use of software package Statistica. M.: Mediasphere; 2002.
Blier P. Neurotransmitter targeting in the treatment of depression. J Clin Psychiatry. 2013;74(suppl 2):19-24. https://doi.org/10.4088/jcp.12084su1c.04
Outhred T, Hawkshead BE, Wager TD, Das P, Malhi GS, Kemp AH. Acute neural effects of selective serotonin reuptake inhibitors versus noradrenaline reuptake inhibitors on emotion processing: Implications for differential treatment efficacy. Neurosci Biobehav Rev. 2013;37(8):1786-1800. https://doi.org/10.1016/j.neubiorev.2013.07.010
Hunter AM, Leuchter AF, Morgan ML et al. Neurophysiologic correlates of the Side Effects in Normal Subjects Randomized to Venlafaxine or Placebo. Neuropsychopharmacol. 2005;30(4):792-799. https://doi.org/10.1038/sj.npp.1300652

Close metadata